{
}
Barclays has initiated coverage of Guardant Health with an Overweight rating and a price target of $60, citing strong revenue growth of 29.2% and positive developments in MRD surveillance coverage. The stock has surged 26.5% recently, nearing its 52-week high, and analysts expect continued growth driven by advancements in cancer diagnostics and expanded Medicare coverage for its tests. Guardant Health's market capitalization stands at $5.83 billion, with a focus on personalized cancer treatment through innovative liquid biopsy technology.
Barclays has initiated coverage on Guardant Health with an Overweight rating and a price target of $60, citing strong revenue growth of 29.2% and positive developments in MRD surveillance. The stock has surged 26.5% recently, nearing its 52-week high, and analysts expect continued growth driven by advancements in cancer diagnostics and expanded Medicare coverage for its tests. Guardant Health's market capitalization stands at $5.83 billion, with a focus on personalized oncology solutions.
UBS has reiterated a Buy rating on Guardant Health, maintaining a $40 price target and naming it a top pick in Life Sciences & Diagnostic Tools. Analyst Dan Leonard highlighted the promising potential of the Shield test for colorectal cancer screening, with anticipated revenue growth and expanded Medicare reimbursement for the Reveal test expected in 2025. Guardant Health's recent partnership with Boehringer Ingelheim and impressive 29.2% revenue growth over the past year further bolster its positive outlook.
UBS has reiterated a Buy rating on Guardant Health, maintaining a $40 price target and naming it a top pick in Life Sciences & Diagnostic Tools. Analyst Dan Leonard highlighted the promising potential of the Shield test for colorectal cancer screening, with anticipated revenue growth and expanded Medicare reimbursement for the Reveal test expected in 2025. Guardant Health reported a 29.2% revenue increase over the past year and is set to disclose Shield test volumes in its upcoming fourth-quarter results on February 20, 2025.
The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
The Global Bromhexine Tablet market is projected to grow from USD 875.5 million in 2023 to USD 1,131.7 million by 2032, with a CAGR of 3.7% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory disorders and increasing demand for expectorants. Key players include Sanofi, Teva, and Boehringer Ingelheim, with market segmentation covering applications, types, and distribution channels across various regions.
OptumRx, the pharmacy benefit manager for UnitedHealth Group, will exclude Sandoz's Hyrimoz and Boehringer Ingelheim's Cyltezo from its 2025 US commercial formularies, favoring Amgen's Amjevita instead. Starting January 1, 2025, Humira will be classified as a tier three product, while Amjevita will be tier two.
Torrent Pharma is enhancing its anti-diabetes portfolio by acquiring three brands from Boehringer Ingelheim, expected to finalize in March 2025. The brands—Cospiaq, Cospiaq Met, and Xilingio—contain Empagliflozin, a key treatment for type 2 diabetes, in a market projected to grow at a 25% CAGR. This move aims to improve patient access to diabetes care in India, which is anticipated to have 12.5 crore diabetes patients by 2045.
Venture capital is increasingly shaping Europe's innovation landscape, with regions like 'Swiss Valley' and 'Silicon Canals' emerging as key hubs. Switzerland's healthcare sector attracts significant investments, while Amsterdam fosters a diverse start-up ecosystem. As sustainability becomes a priority, VC firms are integrating ESG criteria, driving innovation in climate tech and renewable energy.
Venture capital is increasingly shaping innovation in Europe, with regions like 'Swiss Valley' and 'Silicon Canals' emerging as key hubs. In 2024, Europe holds USD 47.2 billion in 'dry powder' for VC investments, particularly in healthcare and technology, despite facing competition and economic uncertainties. The growth of start-ups in these sectors is supported by strong academic institutions and strategic acquisitions by major companies, highlighting a vibrant landscape for future investment.
Boehringer Ingelheim KG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Barclays assigns Overweight rating to Guardant Health with $60 price target
United States Dollar
Guardant Health, Inc.
Boehringer Ingelheim KG
Barclays PLC
USA
Luke Sergott
Show more
15:09 23.01.2025
barclays assigns overweight rating to guardant health with price target of sixty dollars
14:38 23.01.2025
ubs names guardant health top pick with maintained price target of 40
22:39 10.01.2025
ubs names guardant health top pick with maintained price target of forty dollars
22:00 10.01.2025
congestive heart failure market poised for significant growth by 2034
United States Dollar
Mesoblast Ltd
Eli Lilly and Co
Boehringer Ingelheim KG
Bayer AG
Merck & Co., Inc.
Bristol-Myers Squibb Co
Intra-Cellular Therapies, Inc.
BioCardia, Inc.
Novo Nordisk A/S
scPharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Cytokinetics, Incorporated
Novartis AG
Tenax Therapeutics, Inc.
AstraZeneca PLC
Amgen Inc.
Otsuka Pharmaceutical Co. Ltd.
FRA
DEU
ITA
JPN
GBR
USA
Show more
15:50 07.01.2025
global bromhexine tablet market projected to reach 1131 million by 2032
GSK plc
Aspen Pharmacare Holdings Ltd
Boehringer Ingelheim KG
Novartis AG
Sanofi
MYS
IND
PHL
IDN
HKG
SGP
TWN
JPN
THA
AUS
KOR
CHN
VNM
Nidhi Bhavsar
Show more
08:02 14.12.2024
OptumRx favors Amgen's Amjevita over Sandoz and Boehringer biosimilars
17:27 13.12.2024
Torrent Pharma Acquires Three Anti-Diabetes Brands from Boehringer Ingelheim
14:23 04.12.2024
emerging venture capital hubs in europe driving innovation and growth
Swiss Franc
Swedish Krona
Euro
United States Dollar
Novo Nordisk A/S
Johnson & Johnson
Adyen N.V.
Wetransfer B.V.
Boehringer Ingelheim KG
iZettle
Ironwood Pharmaceuticals, Inc.
Elastic N.V.
Mollie
Just Eat Takeaway.com N.V.
Spotify Technology S.A.
PayPal Holdings, Inc.
NLD
GBR
CHE
SWE
Show more
14:08 29.11.2024
emerging venture capital hubs in europe focus on sustainability and innovation
Swiss Franc
Euro
United States Dollar
Swedish Krona
Adyen N.V.
Elastic N.V.
Just Eat Takeaway.com N.V.
Mollie
Wetransfer B.V.
Spotify Technology S.A.
iZettle
PayPal Holdings, Inc.
Johnson & Johnson
Novo Nordisk A/S
Boehringer Ingelheim KG
Ironwood Pharmaceuticals, Inc.
NLD
SWE
GBR
CHE
USA
Show more
14:08 29.11.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Domestic Politics
Banking Regulations
Global Financial Events
Retail and Consumer Goods
CEO Changes
Government Policies
Workplace Trends
Elections & Campaigns
Market Analysis and Predictions
Central Bank Actions
Global Trade Developments
Startups & Entrepreneurship
Hedge Funds & Private Equity
Supply Chain Management
Banking & Investment Regulations
Countries:
Companies:
Tesla, Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Deutsche Bank Money Market PP
JPMorgan Chase & Co.
Barclays PLC
Credit Suisse Strategic Income I
Apple Inc.
CREDIT AGRICOLE
SpaceXCoin USD
Lloyds Banking Group plc
BNP Paribas SA
Amazon.com, Inc.
The Goldman Sachs Group, Inc.
UBS Group AG
Credit Agricole
Banco Santander, S.A.
Reinsurance Group of America, Incorporated
Google Inc.
Amundi S.A.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Offshore Chinese Yuan
Hong Kong Dollar
Norwegian Krone
Filipino Peso
Canadian Dollar
Singapore Dollar
Australian Dollar
Danish Krone
Swedish Krona
Mexican Peso
Qatari Riyal
South African Rand
People: